ATI-2138 exhibits the ability to selectively and potently block interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3), playing a key role in modulating T cell activity involved in ...

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has commenced its Phase 2a clinical trial for ATI-2138, an innovative oral covalent inhibitor targeting ITK and JAK3, aimed at treating ...